SPOTLIGHT: Investors yawn at Maraviroc endorsement

Investors largely shrugged off yesterday's unanimous vote by an FDA panel to back Pfizer's Maraviroc, a first-in-a-class [1] drug for HIV. The therapy will be limited to a narrow share of the market as other HIV drugs with fewer side effects compete for the agency's approval. Report [2]